Figure 1. CellSearch analysis of circulating tumor cells isolated from one patient with NSCLC treated with Nivolumab (pt. 7 of Table 2).

The patient had 7 CTCs, of which 4 PD-L1(+). Figure shows the elongated shape of PD-L1(+) CTCs compared to PD-L1 negative.